Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Praxis Precision Medicines (PRAX) CEO Marcio Souza will participate in a virtual fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025, at 10:00 AM EST. The company focuses on developing therapies for central nervous system (CNS) disorders, specifically targeting neuronal excitation-inhibition imbalance using their Cerebrum™ and Solidus™ platforms. Praxis has a diversified CNS portfolio with four product candidates in clinical development.

“`html

Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on tackling central nervous system disorders, is set to take center stage at a virtual fireside chat. CEO Marcio Souza will engage in a conversation with Truist Securities analyst Joon Lee on August 5, 2025, at 10:00 AM EST. Investors and industry watchers will be eager to hear Souza’s insights on the company’s pipeline and strategy.

Praxis Precision Medicines (NASDAQ: PRAX), un’azienda biofarmaceutica in fase clinica specializzata nello sviluppo di terapie per disturbi del sistema nervoso centrale, ha annunciato la sua prossima partecipazione a un evento virtuale. Il CEO Marcio Souza parteciperà a una conversazione informale moderata dall’analista di Truist Securities Joon Lee il 5 agosto 2025 alle 10:00 EST.

Praxis Precision Medicines (NASDAQ: PRAX), una compañía biofarmacéutica en etapa clínica enfocada en desarrollar terapias para trastornos del sistema nervioso central, ha anunciado su próxima participación en un evento virtual. El CEO Marcio Souza participará en una charla informal moderada por el analista de Truist Securities Joon Lee el 5 de agosto de 2025 a las 10:00 AM EST.

Praxis Precision Medicines (NASDAQ: PRAX)는 중추신경계 질환 치료제 개발에 주력하는 임상 단계 바이오제약 회사로, 곧 개최되는 가상 행사에 참여할 예정임을 발표했습니다. CEO Marcio Souza는 Truist Securities의 애널리스트 Joon Lee가 진행하는 대화에 2025년 8월 5일 오전 10시 EST에 참여할 예정입니다.

Praxis Precision Medicines (NASDAQ : PRAX), une société biopharmaceutique en phase clinique spécialisée dans le développement de thérapies pour les troubles du système nerveux central, a annoncé sa prochaine participation à un événement virtuel. Le PDG Marcio Souza participera à une discussion informelle animée par l’analyste de Truist Securities Joon Lee le 5 août 2025 à 10h00 EST.

Praxis Precision Medicines (NASDAQ: PRAX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Therapien für Erkrankungen des zentralen Nervensystems konzentriert, hat seine bevorstehende Teilnahme an einer virtuellen Veranstaltung angekündigt. CEO Marcio Souza wird an einem Gespräch mit Truist Securities Analyst Joon Lee am 5. August 2025 um 10:00 Uhr EST teilnehmen.

08/04/2025 – 08:24 PM

BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a player in the biopharmaceutical space targeting central nervous system (CNS) disorders, announced that CEO Marcio Souza will participate in a virtual fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025, at 10:00 am EST. The company is focused on translating genetic insights into innovative therapies aimed at addressing neuronal excitation-inhibition imbalance, a key factor in many CNS conditions.

The registration link can be found here.

About Praxis
Praxis Precision Medicines is leveraging genetic insights from epilepsies to develop novel therapies for CNS disorders characterized by imbalances in neuronal activity. Their approach involves a proprietary small molecule platform called Cerebrum™, and an antisense oligonucleotide (ASO) platform named Solidus™, both designed to target shared biological pathways within the brain. This strategy has resulted in a diversified CNS portfolio, with programs spanning epilepsy and movement disorders, and four product candidates currently in clinical development. For additional information, visit www.praxismedicines.com and follow them on Facebook, Instagram, LinkedIn and Twitter/X.

Praxis Precision Medicines to Participate in Upcoming Fireside Chat
Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Investor Contact: 
Praxis Precision Medicines 
[email protected] 
857-702-9452 

Media Contact:
Dan Ferry
Life Science Advisors
[email protected]
617-430-7576

FAQ

When is the Praxis Precision Medicines (PRAX) fireside chat scheduled for?

The fireside chat is scheduled for August 5, 2025 at 10:00 AM EST.

Who will represent Praxis Precision Medicines at the Truist Securities fireside chat?

CEO Marcio Souza will represent Praxis Precision Medicines at the fireside chat.

What is Praxis Precision Medicines’ (PRAX) main focus area?

Praxis Precision Medicines is a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.

Who is hosting the PRAX fireside chat?

The fireside chat will be hosted by Truist Securities analyst Joon Lee.

“`

Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/6412.html

Like (0)
Previous 2 hours ago
Next 1 hour ago

Related News